Clinical Trial

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-01; most recent amendment 2025-12-25.
Status change: Not Yet Recruiting → Recruiting 2024-10-09
Trial Details
NCT Number NCT06534723
Lead Sponsor Sichuan Jishengtang Pharmaceutical Co., Ltd.
Conditions Alzheimer's Dementia
Enrollment 570 participants
Start Date 2024-08-20
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-29